Molecular on/off switch

Journal of Clinical Oncology

Volumn 24, Issue 30, 2006, Pages 4940-4942

  Milton, Daniel T ^a   Riely, Gregory J ^a   Pao, William ^a   Miller, Vincent A ^a   Kris, Mark G ^a   Heelan, Robert T ^b  

^a Thoracic Oncology Service   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10 PROPARGYL 10 DEAZAAMINOPTERIN; AMINOPTERIN DERIVATIVE; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; MITOMYCIN; UNCLASSIFIED DRUG; VINBLASTINE; EPIDERMAL GROWTH FACTOR RECEPTOR; QUINAZOLINE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CASE REPORT; HUMAN; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; MALE; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR GROWTH; ADENOCARCINOMA; DISEASE COURSE; DRUG RESISTANCE; GENETICS; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MUTATION; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME;

EID: 33750614197     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.4410     Document Type: Article

References (13)

1. Fukuoka M, Yano S, Giaccone G, et al: Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21:2237-2246, 2003
2. Kris MG, Natale RB, Herbst RS, et al: Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 290:2149-2158, 2003
3. Perez-Soler R, Chachoua A, Hammond LA, et al: Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238-3247, 2004
4. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
5. Hirota S, Isozaki K, Moriyama Y, et al: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577-580, 1998
6. Kitamura Y, Hirota S, Nishida T: Gastrointestinal stromal tumors (GIST): A model for molecule-based diagnosis and treatment of solid tumors. Cancer Sci 94:315-320, 2003
7. Cools J, DeAngelo DJ, Gotlib J, et al: A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 348:1201-1214, 2003
8. Weinstein IB: Addiction to oncogenes: The Achilles heal of cancer. Science 297:63-64, 2002
9. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792, 2005
10. Pao W, Miller VA, Politi KA, et al; Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73, 2005
11. Kwak EL, Sordella R, Bell DW, et al: Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 102:7665-7670, 2005
12. Gorre ME, Mohammed M, Ellwood K, et al: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880, 2001
13. Tamborini E, Bonadiman L, Greco A, et al: A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 127:294-299, 2004